Beijing Beilu Pharmaceutical
Beijing Beilu Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products in China. The company provides contrast agents, such as gadopentetate meglumine injection, gadobutrol injection, and gadobenate meglumine injection for MRI contrast; and iohexol injection, iopamidol injection, and iodixanol injection for CT contrast, as well as glimepiride … Read more
Beijing Beilu Pharmaceutical (300016) - Total Liabilities
Latest total liabilities as of September 2025: CN¥852.80 Million CNY
Based on the latest financial reports, Beijing Beilu Pharmaceutical (300016) has total liabilities worth CN¥852.80 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Beijing Beilu Pharmaceutical - Total Liabilities Trend (2005–2024)
This chart illustrates how Beijing Beilu Pharmaceutical's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Beijing Beilu Pharmaceutical Competitors by Total Liabilities
The table below lists competitors of Beijing Beilu Pharmaceutical ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sellas Life Sciences Group Inc
NASDAQ:SLS
|
USA | $5.92 Million |
|
WealthNavi Inc
PINK:WNAVF
|
USA | $20.39 Billion |
|
Corporacion Acciona Energias Renovables SA
MC:ANE
|
Spain | €8.96 Billion |
|
Serve Robotics Inc. Common Stock
NASDAQ:SERV
|
USA | $15.24 Million |
|
Yijiahe Technology Co Ltd
SHG:603666
|
China | CN¥1.06 Billion |
|
Hatsun Agro Product Limited
NSE:HATSUN
|
India | ₹26.00 Billion |
|
FARM FRESH BERHAD
KLSE:5306
|
Malaysia | RM714.65 Million |
Liability Composition Analysis (2005–2024)
This chart breaks down Beijing Beilu Pharmaceutical's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.22 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Beijing Beilu Pharmaceutical's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Beijing Beilu Pharmaceutical (2005–2024)
The table below shows the annual total liabilities of Beijing Beilu Pharmaceutical from 2005 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.15 Billion | +11.12% |
| 2023-12-31 | CN¥1.03 Billion | +15.78% |
| 2022-12-31 | CN¥892.27 Million | +9.05% |
| 2021-12-31 | CN¥818.22 Million | -14.37% |
| 2020-12-31 | CN¥955.50 Million | +451.32% |
| 2019-12-31 | CN¥173.31 Million | +108.99% |
| 2018-12-31 | CN¥82.93 Million | +15.74% |
| 2017-12-31 | CN¥71.65 Million | +31.71% |
| 2016-12-31 | CN¥54.40 Million | -53.66% |
| 2015-12-31 | CN¥117.39 Million | -51.22% |
| 2014-12-31 | CN¥240.67 Million | +293.50% |
| 2013-12-31 | CN¥61.16 Million | +2.56% |
| 2012-12-31 | CN¥59.64 Million | +79.71% |
| 2011-12-31 | CN¥33.19 Million | +343.20% |
| 2010-12-31 | CN¥7.49 Million | -57.46% |
| 2009-12-31 | CN¥17.60 Million | -33.62% |
| 2008-12-31 | CN¥26.52 Million | -48.36% |
| 2007-12-31 | CN¥51.36 Million | -5.07% |
| 2006-12-31 | CN¥54.10 Million | +26.55% |
| 2005-12-31 | CN¥42.75 Million | -- |